Disease · MONDO_0019082

bullous pemphigoid

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. bullous pemphigoid. Diseases, record MONDO_0019082. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019082

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: bullous pemphigoid; Open Targets
Open Targets ID: MONDO_0019082; Open Targets
Other names: Bullous pemphigoid (disorder), Pemphigoid, Bullous; Open Targets
Disease Ontology: DOID:8506; Disease Ontology
MeSH: D010391; MeSH
NCI Thesaurus: C84389; NCI Thesaurus
Orphanet: ORPHA:703; Orphanet
Highest stage of its drugs: Approval, for 1 of its 29 drugs, from ClinicalTrials.gov; Open Targets

Drugs29

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DUPILUMAB	CHEMBL2108675	Antibody	Approval	ClinicalTrials.gov	3	3	3	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
NOMACOPAN	CHEMBL4297928		Phase 3	ClinicalTrials.gov and TTD	3	2	1	Drugs and targets
CLOBETASOL PROPIONATE	CHEMBL1159650	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
EFGARTIGIMOD ALFA	CHEMBL4297551	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
HUMAN IMMUNOGLOBULIN G	CHEMBL1201599		Phase 3	ClinicalTrials.gov	2	2	0	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BENRALIZUMAB	CHEMBL1742991	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OMALIZUMAB	CHEMBL1201589	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
STAPOKIBART	CHEMBL5095324	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 29

See all 29 drugs

Targets28

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	4	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
IGHE	Immunoglobulin heavy constant epsilon	2	Ig epsilon chain C region inhibitor	Phase 3	https://conductscience.org/library/genes/3497	Drugs and targets
IL12B	Interleukin-12	2	Interleukin-12 inhibitor; Interleukin-23 inhibitor	Phase 2	https://conductscience.org/library/genes/3593	Drugs and targets
IL23A	Interleukin-23	2	Interleukin-23 inhibitor	Phase 2	https://conductscience.org/library/genes/51561	Drugs and targets
C1S	Complement C1s subcomponent	1	Complement C1s inhibitor	Phase 1	https://conductscience.org/library/genes/716	Drugs and targets
C5	Complement C5	1	Complement C5 inhibitor	Phase 3	https://conductscience.org/library/genes/727	Drugs and targets
C5AR1	C5a anaphylatoxin chemotactic receptor 1	1	C5a anaphylatoxin chemotactic receptor inhibitor	Phase 2	https://conductscience.org/library/genes/728	Drugs and targets
CCL11	Eotaxin	1	Eotaxin inhibitor	Phase 2	https://conductscience.org/library/genes/6356	Drugs and targets
CXCR1	C-X-C chemokine receptor type 1	1	Interleukin-8 receptor A modulator	Phase 2	https://conductscience.org/library/genes/3577	Drugs and targets
CXCR2	C-X-C chemokine receptor type 2	1	Interleukin-8 receptor B modulator	Phase 2	https://conductscience.org/library/genes/3579	Drugs and targets

1 to 10 of 28

See all 28 targets

Trials26

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04206553	A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid	Phase 2/3	106	2026-03-06	Bullous Pemphigoid	DUPILUMAB	Its record names the disease	ClinicalTrials.gov
NCT05267600	A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid	Phase 2/3	98	2025-10-23	Bullous Pemphigoid	EFGARTIGIMOD ALFA	Its record names the disease	ClinicalTrials.gov
NCT04612790	A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.	Phase 3	67	2024-11-29	Bullous Pemphigoid	BENRALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT05681481	A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid	Phase 3	64	2026-02-25	Bullous Pemphigoid	EFGARTIGIMOD ALFA	Its record names the disease	ClinicalTrials.gov
NCT01688882	Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment	Phase 2	20	2016-04-28	Bullous Pemphigoid	LIGELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02226146	Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid	Phase 2	11	2025-11-26	Pemphigoid, Bullous	BERTILIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00286325	Rituximab in the Treatment of Patients With Bullous Pemphigoid	Phase 1/2	8	2012-10-22	Bullous Pemphigoid	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT04499235	A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid	Phase 2	6	2023-09-14	Pemphigoid, Bullous	LAZUCIRNON, MOMETASONE FUROATE	Its record names the disease	ClinicalTrials.gov
NCT03099538	Ixekizumab in the Treatment of Bullous Pemphigoid	Phase 2	4	2020-05-21	Bullous Pemphigoid, Pemphigoid	IXEKIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02313870	Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid	Phase 3	322		Bullous Pemphigoid	CLOBETASOL PROPIONATE, METHOTREXATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 26

See all 26 trials

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dupilumab Q2W vs Placebo: Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE) Through Week 52	51 of 53	51 of 53	106	NCT04206553	Trial comparisons
Dupilumab Q2W vs Placebo: Number of Participants With At Least One Serious TEAE Through Week 52	12 of 53	16 of 53	106	NCT04206553	Trial comparisons
Dupilumab Q2W vs Placebo: deaths from any cause	2 of 53	6 of 53	106	NCT04206553	Trial comparisons
Dupilumab Q2W vs Placebo: Number of Participants With At Least One TE Adverse Event of Special Interest (AESI) Through Week 52	4 of 53	0 of 53	106	NCT04206553	Trial comparisons
Dupilumab Q2W vs Placebo: serious adverse events	20 of 53	21 of 53	106	NCT04206553	Trial comparisons
Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Participants Who Achieve an IGA-BP Score of 0 While Off OCS Therapy for ≥8 Weeks at Week 36	9 of 50	3 of 48	98	NCT05267600	Trial comparisons
Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Participants With CDA Who Remained Free of Relapse Through Week 36	7 of 50	8 of 48	98	NCT05267600	Trial comparisons
Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Participants With CRoff at Week 36	8 of 50	2 of 48	98	NCT05267600	Trial comparisons
Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Participants With CRmin at Week 36	8 of 50	3 of 48	98	NCT05267600	Trial comparisons
Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Participants Who Receive Rescue Therapy Before Week 36	19 of 50	18 of 48	98	NCT05267600	Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41807108	RESULT	1	PubMed
39310808	RESULT	1	PubMed
30837635	RESULT	1	PubMed
38508975	DERIVED	1	PubMed
38443648	DERIVED	1	PubMed
18087004	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019082

GET https://conductscience.org/api/diseases/v1/MONDO_0019082/drugs?page=2

API reference For AI assistants